Sunitinib, a broad-spectrum tyrosine kinase inhibitor that primarily targets VEGF pathways but has some collateral inhibition of these pathways, can be used for BRAF-wild-type or drug-resistant BRAF-mutant melanomas, but response rates are low and toxicity is significant [50,56]. Here, VEGFA is linked to melanoma.